Company Overview - Immvira Bioscience Inc. (亦诺微医药) is a biotechnology company focused on clinical demand-driven solutions, specializing in the discovery, development, production, and commercialization of novel oncolytic immunotherapies and engineered exosome therapies [4] - The company has established a product pipeline that includes two oncolytic immunotherapy products targeting solid tumors and five engineered exosome products with clinical application potential or direct commercialization prospects [4] - The core product, MVR-T3011, is a phase II oncolytic immunotherapy product based on herpes simplex virus type 1 (HSV-1), which combines strong tumor lysis effects with the expression of anti-PD-1 antibodies and IL-12 [4] Financial Information - The company reported revenues of RMB 6.772 million, RMB 3.2 million, and RMB 1.305 million for the fiscal years ending December 31, 2023, December 31, 2024, and the nine months ending September 30, 2025, respectively [6][7] - The company incurred losses of approximately RMB 481.753 million, RMB 523.755 million, and RMB 337.910 million for the same periods [8] - Research and development expenses were significant, amounting to RMB 136.201 million for 2023 and RMB 111.542 million for 2024 [6] Industry Overview - The global oncolytic immunotherapy market is currently in its early stages, characterized by a limited number of commercialized products and low clinical adoption rates [9] - The market is expected to experience rapid expansion, with projections indicating growth from USD 87.1 million in 2024 to USD 1.56 billion by 2028, representing a compound annual growth rate (CAGR) of 105.7% [11] - In China, the oncolytic virus drug market is anticipated to grow from USD 6.3 million in 2024 to USD 223 million by 2028, with a CAGR of 143.9% [14]
新股消息 | 亦诺微医药递表港交所 为一家专注于临床需求导向的生物科技公司
Xin Lang Cai Jing·2026-01-14 23:53